Pre-IND Meeting Confirms 505(b)(2) Pathway for Bisantrene
Filed with ASX · · 1 page · English
Earlier from Racura Oncology
- Race Oncology Update & Investor Presentation
- Race Signs Agreement with US Based IriSys LLC
- Race Signs Key Manufacturing Agreement for Bisantrene
- Race Signs NPP Partnership with CarthaGenetics in Europe
- Race signs agreement with Camargo Pharmaceutical
Later from Racura Oncology
- Bisantrene License Agreement for Korea
- Race Announces NCI Collaboration
- Race Joint Venture with TargImmune
- Race Completes Over-Subscribed $2.5 Million Placement
- Peer-Reviewed The Rediscovery of Bisantrene Published
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology